caedooncology

Caedo Oncology AS is a pioneering biotechnology company focused on developing advanced monoclonal antibody therapies for cancer treatment. Operating in the immunotherapy market, Caedo Oncology serves patients and healthcare providers by offering innovative solutions that selectively target cancer cells, minimizing damage to healthy cells. The company's flagship product, CO-1, is a novel bifunctional anti-CD47 monoclonal antibody that not only blocks CD47 interactions but also induces rapid programmed cell death in cancer cells, setting it apart from other CD47 antibodies.

Caedo Oncology's business model revolves around research and development, leveraging a team of scientists and advisors with expertise in biology, molecular biology, immunology, and chemistry. The company generates revenue through partnerships, licensing agreements, and potential future sales of its proprietary therapies.

The primary market for Caedo Oncology includes oncology clinics, hospitals, and research institutions focused on cancer treatment. The company is backed by Sarsia Seed Fond II AS, a Norwegian early-stage venture capital fund specializing in biotechnology and life sciences, which holds a 44% stake. The remaining 34% of shares are distributed among the founders and management team.

Keywords: monoclonal antibodies, cancer immunotherapy, CD47, programmed cell death, biotechnology, oncology, research and development, venture capital, innovative therapies, selective targeting.